
Dopamine Capital
787 posts

Dopamine Capital
@DA_Capital_
Investing since 15 —— Just the stock journal of @DA_ResearchLabs


🚨🚨🚨 The 2nd case of amlitelimab (OX40) induced Kaposi sarcoma was just disclosed by $SNY today at AAD. Somehow $NKTR is still in the double digits…*surely* the complete death of Amlitelimab would change this? Up until very recently (weeks) $SNY has *still* been projecting amlitelimab to be a $3-$5B peak sales drug in atopic derm ALONE. If Amli is discontinued (as it should be) $NKTR’s rezpeg would be slated to be the next new MoA on the market for AtD, and THE ONLY non-IL4/13 biologic besides the ineffective Nemluvio (…which is still going to be a $4B+ peak mega blockbuster despite its lack of efficacy……..) Right now, $NKTR’s efficacy vastly exceeds nemluvio’s and beats OX40’s by a healthy ~10% delta. All of that WITHOUT causing cancer. $3-$5B peak for OX40??? What’s $NKTR worth? OH! And that’s just the sales projections for AtD…I expect that soon the market will wake up to the fact that Rezpeg is a legitimate drug for alopecia areata too, which currently seems to be priced totally out of the stock. IMO $NKTR already went into the weekend the most mispriced name in my book. Now the death knell for OX40 is coming into view. $NKTR is *CLEARLY* the biggest direct beneficiary of this in the entire market. As always, I’m biased, but I’m just mind blown that this isn’t already a $100 stock. Let’s see if the market starts to accept that OX40 is finally done for. That could be explosive news for $NKTR.








🚨🇶🇦🇮🇷🇺🇸 BREAKING: Qatar's energy production will NOT RESUME until the war ends - Qatari Energy Minister









Our Q4 & Full Year 2025 Results Are Here. Energy Vault capped a transformational 2025 as we continue to build the energy infrastructure backbone for the global energy transition and AI economy. See below for our key highlights from Q4 and FY 2025: -Contract revenue backlog reached $1.3B, up 3x YoY and 42% sequentially -Q4 2025 revenue of $153.3M, up from $33.5M in the prior year; FY 2025 revenue of $203.7M, up 340%+ YoY -Q4 2025 Adjusted EBITDA turned positive to $9.8M — our first positive Adjusted EBITDA quarter -Cash climbed to $103.4M, up 67% sequentially and up over 300% YoY -Total MW contracted, in operation, and under construction grew from 65 MW to 540 MW in the last 12 months -2026 guidance: $225–$300M revenue, $150–$200M total cash at year-end Read the full press release here for additional details on our Q4 and full year progress: hubs.la/Q047ddW60 Join today's earnings call to learn more at 4:30 PM ET. Click here to access the webcast: hubs.la/Q047dlvN0 Dial-in: 1-877-704-4453 (US) | 1-201-389-0920 (Int'l) - Request Energy Vault Holdings earnings call








